ClinicalTrials.gg
CompletedNCT05153434Updated Sep 8, 2026Results posted

A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome

A Phase 2 interventional study of ARD-101 in Prader-Willi Syndrome, sponsored by Aardvark Therapeutics, Inc.. Completed at 2 sites in United States. Open to participants aged 17 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Aardvark Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
19
Allocation
Non-randomized
Ages
17 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies in Prader-Willi Syndrome with a site in United States — 9 open to participants now, 14 under way, 3 of them phase 3. Prader-Willi Syndrome · United States.

Enrollment
32nd of 58
19 · median 23
Started
2022
with 3 others
Phase 2
17 of 69
1 open now
Registered
45th of 69
by date
Lead sponsor
3 of 69
Aardvark Therapeutics, Inc.

Among the 69 studies in Prader-Willi Syndrome with a site in United States, this one is the 32nd largest by enrollment of the 58 interventional ones that give a count, is one of 4 that started in 2022, is one of 17 in phase 2, and was the 45th registered.

Prader-Willi Syndrome

144 studies on the registry are indexed under Prader-Willi Syndrome; 23 are open to participants now.

Browse Prader-Willi Syndrome studies →

Open to participants now

9 of the 69 studies in Prader-Willi Syndrome with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 16 Prader-Willi Syndrome studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: 17 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Prader-Willi Syndrome with a site in United States, or all of them as a file.
02

Study summary

A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of ARD-101 in Patients with Prader-Willi Syndrome

Read the detailed description

This is a Phase 2, open-label study to investigate the effects of ARD-101 in subjects with Prader-Willi Syndrome. The study will consist of a Screening Period (up to 28 days), a Treatment Period (28 days), and a Follow-up Period (End-of-Study Visit within 14 days after receiving the last dose of ARD-101). The screening procedures will be initiated upon completion of the informed consent process. Following completion of screening procedures and confirmation of eligibility, subjects will be enrolled to receive ARD-101 in an outpatient setting and will be instructed to visit the clinical center periodically for safety and efficacy assessments.

ARD-101 will be provided as a fixed dose of 200 mg BID for 28 days (Group 1) and then in a dose escalation of 1 week at 400 mg BID, 1 week at 600 mg BID, then 2 weeks at 800 mg BID (Group 2).

03

Conditions studied

  • Prader-Willi Syndrome

Browse trials for

04

Who can participate

Ages eligible
17 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects, 17-65 years of age
  • Provide voluntary, written (parent(s) / legal guardian(s) of participant); provide voluntary, written assent (participants, as appropriate)
  • PWS due to chromosome 15 micro-deletion, maternal uniparental disomy, or imprinting defect, confirmed by fluorescent in situ hybridization, chromosomal microarray, and/or methylation studies
  • ≥ 18.5 kg/m²
  • Qualifying HQ-CT score

Exclusion criteria

Exclusion Criteria:

  • Use of weight loss agents, including herbal medication, within 3 months prior to enrollment
  • Diagnosis of schizophrenia, bipolar disorder, personality disorder, or other DSM-III disorders which the investigator believes will interfere significantly with study compliance
  • illness in the 8 weeks prior to enrollment
  • Current, clinically significant liver, renal, pulmonary, cardiac, oncologic, or gastrointestinal (GI) disease
  • Diagnosis of type 1 diabetes mellitus or other active endocrine disorders (e.g., Cushing syndrome, or thyroid dysfunction except if on stable adequate thyroid or replacement supplement)
  • Significant history of abuse of drugs within 1 year prior to enrollment or a positive Drugs of Abuse (DOA) test at screening
  • History of alcohol abuse within 1 year prior to enrollment or currently drinks in excess of 21 units per week (3 servings or units/day)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    ARD-101 (Fixed Dose)

    ARD-101: 4 weeks dosing at 200 mg BID (twice daily)

    Drug: ARD-101

  • Experimental
    ARD-101 (Dose Escalation)

    ARD-101: 1 week at 400 mg BID (twice daily), second week at 600 mg BID, third and fourth weeks at 800 mg BID. Oral administration.

    Drug: ARD-101

Interventions

  • Oral administration of ARD-101 taken BID (twice daily) for 28 days.

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment Emergent Adverse Events (TEAE)

    The incidence of treatment emergent adverse events (TEAE) reported through the 28 days of treatment and the 14 days post treatment phase. TEAEs were those events occurring after treatment began.

    Time frame: Adverse Events were collected from time of informed consent through end of study; approximately 70 days (28 days of screening, 28 days of treatment, 14 days post treatment follow up).

Secondary outcomes

  1. Efficacy Evaluation of Hyperphagia in Prader-Willi Syndrome

    Quantitative evaluation of hyperphagia via the Hyperphagia Questionnaire for Clinical Trials (HQ-CT). The HQCT is a 9-item hyperphasia questionnaire which is validated for use in PWS clinical trials. Score will range from 0 (no hyperphagia behaviors) to 36 (most severe hyperphagia behaviors)

    Time frame: Baseline, Day 15, Day 28

  2. Change in Body Weight

    Total weight change at the end of treatment (day 28) from baseline

    Time frame: Baseline to day 28

07

Results

Posted Sep 8, 2026

Participant flow

Participant flow — Overall Study
MilestoneGroup 1 (Fixed Dose)Group 2 (Dose Escalation)
Started136
Completed126
Not completed10
Withdrew: Adverse event10

Outcome measures

SecondaryEfficacy Evaluation of Hyperphagia in Prader-Willi Syndrome

Quantitative evaluation of hyperphagia via the Hyperphagia Questionnaire for Clinical Trials (HQ-CT). The HQCT is a 9-item hyperphasia questionnaire which is validated for use in PWS clinical trials. Score will range from 0 (no hyperphagia behaviors) to 36 (most severe hyperphagia behaviors)

Time frame:
Baseline, Day 15, Day 28
Reported as:
Mean · score on a scale
Efficacy Evaluation of Hyperphagia in Prader-Willi Syndrome
score on a scaleGroup 1 (Fixed Dose)Group 2 (Dose Escalation)
Baseline18 ± 4.4120.2 ± 4.88
Change from Baseline to Day 15-9.2 ± 4.26-5.0 ± 6.51
Change from Baseline to Day 28-9.0 ± 4.80-4.0 ± 8.74
PrimaryIncidence of Treatment Emergent Adverse Events (TEAE)

The incidence of treatment emergent adverse events (TEAE) reported through the 28 days of treatment and the 14 days post treatment phase. TEAEs were those events occurring after treatment began.

Time frame:
Adverse Events were collected from time of informed consent through end of study; approximately 70 days (28 days of screening, 28 days of treatment, 14 days post treatment follow up).
Reported as:
Count of participants · Participants
Incidence of Treatment Emergent Adverse Events (TEAE)
ParticipantsARD-101 (Fixed Dose)ARD-101 (Dose Escalation)
Incidence of Treatment Emergent Adverse Events (TEAE)85
SecondaryChange in Body Weight

Total weight change at the end of treatment (day 28) from baseline

Time frame:
Baseline to day 28
Reported as:
Mean · kg
Change in Body Weight
kgGroup 1 (Fixed Dose)Group 2 (Dose Escalation)
Change in Body Weight0.23 ± 1.5561.02 ± 1.698

Adverse events

Collected over Adverse events (AEs) were collected and recorded for each patient from the date the ICF was signed until the end of follow up, up to 70 days. A treatment emergent adverse event (TEAE) is defined as an adverse event that occurs or worsens during a defined treatment period, up to 42 days (i.e., 28 days of treatment plus 14 days of follow up).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1 (Fixed Dose)0/13 (0%)0/13 (0%)8/13 (61.5%)
Group 2 (Dose Escalation)0/6 (0%)0/6 (0%)5/6 (83.3%)
Most frequent other events
Showing 10 of 18
Most frequent other events
EventGroup 1 (Fixed Dose)Group 2 (Dose Escalation)
HeadacheNervous system disorders3/133/6
DysgeusiaNervous system disorders1/132/6
IrritabilityPsychiatric disorders0/132/6
DiarrheaGastrointestinal disorders2/131/6
NauseaGastrointestinal disorders1/131/6
AgitationPsychiatric disorders0/131/6
Upper Respiratory Tract InfectionInfections and infestations0/131/6
Gait DisturbanceGeneral disorders0/131/6
TremorNervous system disorders1/130/6
Abdominal PainGastrointestinal disorders1/130/6

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Group 1 (Fixed Dose)Group 2 (Dose Escalation)Total
<=18 years112
Between 18 and 65 years12517
>=65 years000
Age, Continuous
Age, Continuous(years)Group 1 (Fixed Dose)Group 2 (Dose Escalation)Total
Mean23.8 ± 7.8121.2 ± 3.5422.9 ± 6.76
Sex: Female, Male
Sex: Female, Male(Participants)Group 1 (Fixed Dose)Group 2 (Dose Escalation)Total
Female9312
Male437
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1 (Fixed Dose)Group 2 (Dose Escalation)Total
Hispanic or Latino101
Not Hispanic or Latino12618
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1 (Fixed Dose)Group 2 (Dose Escalation)Total
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander101
Black or African American011
White11516
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Group 1 (Fixed Dose)Group 2 (Dose Escalation)Total
United States13619
08

Study locations

2 sites
  • Stanford University
    Palo Alto, California 94304, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Sep 2024, 27 months.

Results were first posted in Sep 2026, 1 year 11 months after primary completion.

Of 11 phase 2 interventional studies under Prader-Willi Syndrome, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 27. This study's 27 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2021
First posted
Dec 10, 2021
StartActual
May 27, 2022
Primary completionActual
Sep 24, 2024
CompletionActual
Sep 24, 2024
Results first posted
Sep 8, 2026
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05153434
Lead sponsor
Aardvark Therapeutics, Inc.
Collaborators
Children's Hospital Colorado, Stanford University
Responsible party
Sponsor
First posted
Dec 10, 2021
Start date
May 27, 2022
Primary completion
Sep 24, 2024
Completion
Sep 24, 2024
Results posted
Sep 8, 2026
Last update
Sep 8, 2026

Study contacts

Shawn McCandless, MD
principal investigator · Children's Hospital Colorado

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denatonium acetate monohydrate

Start the discussion